Navigation Links
VOICE study, a major HIV prevention trial for women, is launched in Zimbabwe
Date:9/16/2009

gel, contains the activated form of the same ingredient in the tenofovir oral tablet. It is among a newer class of candidate microbicides substances intended to reduce or prevent the sexual transmission of HIV and other sexually transmitted infections when applied topically inside the vagina or rectum with specific activity against HIV.

Women in VOICE are randomly assigned to one of five study groups. Two groups will apply gel every day either tenofovir gel or a placebo gel with no active ingredient. Three groups will be assigned to daily tablet regimens, taking either tenofovir, Truvada or a placebo tablet. Because the study is blinded, neither the participants nor the researchers will know who is in which gel or tablet group. Women will use the same product every day the entire time they are in the study, which is expected to be an average of 22.5 months.

All participants will receive regular HIV testing and risk-reduction counseling, condoms, and testing for sexually transmitted infections (STIs). Staff will refer any participant who acquires HIV or an STI during the study to appropriate treatment and care in her community.

Researchers at the Uganda and Zimbabwe sites are also conducting a companion study called VOICE B, or the Bone Mineral Density Sub-study. VOICE B will involve about 300 women who have been randomized to the oral tablet groups to determine the potential effects, if any, that the oral ARVs may have on bone health in HIV-negative women.

Both studies were designed according to the most rigorous international medical practice and ethical standards and include numerous measures, beginning at the site level, intended to protect the safety and well-being of participants. All women participating in VOICE and VOICE B will provide written informed consent through a process that ensures they understand the procedures, as well as possible risks and benefits of the study. Safety will be monitored closely throughout th
'/>"/>

Contact: Lisa Rossi
rossil@upmc.edu
412-916-3315
Microbicide Trials Network
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Forterus Inc. Executives to Be Interviewed on VoiceAmerica
2. Audiopoint Adds Voice to Healthcare Reform Debate
3. AMR Research Analyst Named One of the Most Inspiring Individuals in Life Sciences by PharmaVOICE
4. Healthcare Providers Employ GHX OnDemand AP(SM) Solution to Automate and Streamline Invoice-to-Payment Process
5. Yorkshire and Humber NHS Procurement Hub Selects BigHand Voice Platform
6. Introducing Healthspottr: The New Voice of Healthcare Innovation
7. The Empire State Healthcare Coalition Voices Concern Over the Affordable Health Choices Act
8. The New York Times Website Patient Voices Series Features People Affected by Lupus
9. Riverside Partners Completes Growth Equity Investment in Vocollect, the Leader in Voice Solutions for Supply-Chain and Healthcare Workforce Management
10. U-M study finds voice box can be preserved, even with the largest cancers
11. Skilled Nursing Care Coalition Voices Alarm About State Budget
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... In a world enveloped in ... has lessened, and due to the intrusion of ... sleep has eroded. According to Web MD, one ... (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably high number ... incalculable amount, leading not only to dissatisfied employers, ...
(Date:11/27/2014)... 2014 An inventor from Buffalo, N.Y., ... of life, and she wants to lessen its impact. ... I decided that there needed to be a way ... Easy to use and producible in design variations, the ... private areas throughout the day. It avoids bad odors, ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Nearly ... been filed in a consolidated litigation now underway ... , Documents recently updated in the Philadelphia ... in the state proceeding, all of which involve ... and other psychiatric conditions. Many of the cases ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
(Date:11/27/2014)... meals can pose a challenge for people who have ... Many traditional Thanksgiving dishes -- such as turkey, corn, ... "when it comes to pies, stuffing, gravy, etc., gluten-free ... director of the Gluten and Allergic Digestive Disorders program ... said in a center news release. "For those ...
Breaking Medicine News(10 mins):Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2
... ptient with a turbocharger for the heart called C-Pulse.// ... moderate heart problems, who are still not ill enough to ... These patients may be those who may feel extreme tiredness, ... help from medications. ,The new device is a balloon ...
... may have less tolerance to alcohol intakes than men, suggests ... 2005//. ,Researchers of University of Pittsburgh School of Medicine ... things to women than their male counterparts. Women may be ... men even if they have the same amount of the ...
... colonoscopy may be the favorable method to screen women// ... cancer, flexible sigmoidoscopy is used to detect colorectal neoplasias, ... dysplasia, or cancer. Researchers had used colonoscopy to detect ... women who were referred for colon-cancer screenings. ,Of the ...
... that extracts of the grapefruit seeds contain antioxidants ... a fruit, grapefruit had been associated with acidity ... and helpful ingredients that have healing properties. Researchers ... and presented their study findings at the Digestive ...
... research presented at Digestive Disease Week 2005, antidepressants ... depression, also known as unipolar depression, is often ... inhibitors (SSRIs) by physicians. , ,Previous research ... (NSAID) can cause increased bleeding and hemorrhage in ...
... Baptist Medical Center, US, have found that low doses ... and thus limits the side effects of the therapy ... chemotherapy given to children suffering from Acute Lymphblastic Leukemia ... cancer were administered very limited dosage of chemotherapy and ...
Cached Medicine News:
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
(Date:11/26/2014)... 25, 2014   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will attend The Benchmark Company, LLC,s Micro Cap ... will be held at The Palmer House Hilton, 17 E. ... a.m. to 2:30 p.m. Please email hska@haydenir.com or ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... Safety and Efficacy Data Presented at 1st IASLC-ESMO European Lung ... ... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company ... 2,clinical trial of picoplatin confirming previously announced interim,results showing a survival ...
... 23 Archus Orthopedics, Inc.,announced today that it ... TFAS-C(TM) system, the newest addition to the company,s ... which degenerative changes in,the facet joints result in ... legs. Traditionally, patients with moderate to,severe spinal stenosis ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 2Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 3Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 4First Human Implant of New Archus Orthopedics Facet Replacement System 2
... highest g-force ever. But optimal productivity in ... MAX combines maximum force, capacity, and ease ... worlds apart from any other system. With ... efficiency, Optima takes productivity to the MAX. ...
... ultracentrifuge is designed to play a ... if research involves proteomics, cytomics or ... computer, enhanced firmware, powerful Optima eXPert ... Optima L-XP delivers superior functionality, optimized ...
... The Dimension Xpand integrated chemistry ... compact footprint to the smaller laboratory. ... The Dimension Xpand integrated chemistry system ... tailored for the low-volume environment, in ...
The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability....
Medicine Products: